Abstract
Loss of heterozygosity (LOH) at human chromosome 18q, which includes the gene Deleted in Colorectal Cancer (DCC), has been linked to colorectal and many other human cancers. DCC encodes the receptor for the axon guidance molecule Netrin (Net) and functions during neural development in a variety of organisms. However, since its discovery in the 1990s, the status of DCC as a tumor suppressor has been debated, primarily due to a lack of support for this hypothesis in animal models. A recent study from our laboratory capitalized on the genetic tractability of Drosophila melanogaster to demonstrate that this gene functions as an invasive tumor suppressor, thereby providing the first direct link between DCC loss and metastatic phenotypes in an animal model for cancer. Two subsequent studies from other laboratories have demonstrated that DCC suppresses tumor progression and metastasis in murine colorectal and mammary tumor models. Combined, these findings have prompted the rebirth of DCC as a tumor suppressor and highlighted the need for continued analysis of DCC function in animal models for human cancer.
Keywords: Apoptosis, axon guidance, cancer, DCC, Drosophila melanogaster, metastasis, netrin, tumor suppressor, LOH, metastatic phenotype.
Current Drug Targets
Title:Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Volume: 13 Issue: 11
Author(s): Molly Duman-Scheel
Affiliation:
Keywords: Apoptosis, axon guidance, cancer, DCC, Drosophila melanogaster, metastasis, netrin, tumor suppressor, LOH, metastatic phenotype.
Abstract: Loss of heterozygosity (LOH) at human chromosome 18q, which includes the gene Deleted in Colorectal Cancer (DCC), has been linked to colorectal and many other human cancers. DCC encodes the receptor for the axon guidance molecule Netrin (Net) and functions during neural development in a variety of organisms. However, since its discovery in the 1990s, the status of DCC as a tumor suppressor has been debated, primarily due to a lack of support for this hypothesis in animal models. A recent study from our laboratory capitalized on the genetic tractability of Drosophila melanogaster to demonstrate that this gene functions as an invasive tumor suppressor, thereby providing the first direct link between DCC loss and metastatic phenotypes in an animal model for cancer. Two subsequent studies from other laboratories have demonstrated that DCC suppresses tumor progression and metastasis in murine colorectal and mammary tumor models. Combined, these findings have prompted the rebirth of DCC as a tumor suppressor and highlighted the need for continued analysis of DCC function in animal models for human cancer.
Export Options
About this article
Cite this article as:
Duman-Scheel Molly, Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530215
DOI https://dx.doi.org/10.2174/138945012803530215 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Papain Loaded Solid Lipid Nanoparticles for Colorectal Cancer Therapy
Current Cancer Therapy Reviews Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Application of Liposomes in Cancer Therapy: An Assessment of the Advancement of Technology Through Patent Documents
Recent Patents on Nanotechnology The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons
Current Medicinal Chemistry Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Ribosomal Proteins and Colorectal Cancer
Current Genomics Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets Calcimimetic Drugs and Biomarkers
Recent Patents on Biomarkers Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design